<DOC>
	<DOCNO>NCT00292071</DOCNO>
	<brief_summary>This open-label study MK0991 child 3 24 month age new onset fever neutropenia . The purpose study investigate plasma drug level caspofungin .</brief_summary>
	<brief_title>Open , Pharmacokinetic Study Caspofungin Acetate Immunocompromised Young Children With Febrile Neutropenia ( 0991-042 )</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Patient 3 24 month age one follow condition : Leukemia , lymphoma , cancer Bone marrow peripheral stem transplantation High dose chemotherapy lead decrease white blood cell Aplastic anemia Patient absolute neutrophil count &lt; 500 mm3 ( specific type white blood cell fight infection ) AND least one record fever &gt; 38 degreesC ( oral oral equivalent ) within 72 hour screen . Patient &lt; 3 month &gt; 24 month age time study drug administration Patient proven probable invasive fungal infection time enrollment Patient certain blood clot liver function abnormality Patient hemodynamically unstable , exhibits hemodynamic compromise expect survive least 5 day Patient take rifampin , cyclosporin A , phenytoin , carbamazepine , phenobarbital .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>